Skip to content
Screener

Bausch + Lomb BLCO Restricted Cash

Restricted Cash at other companies

Glaukos logo
GlaukosGKOS
$3.12M-18.8%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$1.61M0.0%
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
$0-100%
Bausch Health Companies logo
Bausch Health CompaniesBHC
$13M-43.5%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$10.2M-48.5%
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO

Other financials

Income statement

See full
Revenue$1.4B+9.1%
Operating income$83.0M+855%
Net income-$14.0M+77.4%
EPS (diluted)-$0.04+77.8%

Balance sheet

See full
Cash & equivalents$378.0M+39.0%
Total debt$5.1B+2.4%
Total equity$6.4B-1.0%
Total assets$13.9B+0.2%

Cash flow

See full
Operating cash flow$153.0M+337%
CapEx$71.0M-20.2%
Free cash flow$82.0M+252%

Valuation

See full
Market cap$6.01B+24.5%
Enterprise value$10.71B+12.6%
P/S1.1×+0.1×

Profitability

See full
Operating margin6.1%+5.3pp
Net margin-3.2%-1.0pp
FCF margin-3.4%0.0pp

Returns & leverage

See full
Return on equity-2.7%-0.7pp
Debt / equity0.8×0.0×
Current ratio1.5×0.0×

Where this comes from

Reported directly by Bausch + Lomb in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashCurrent.

The source filing: Bausch + Lomb’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 4:17 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001860742-26-000088
Line itemJune 30, 2026December 31, 2025
Assets
Current assets:
Cash and cash equivalents$367$383
Restricted cash1114
Trade receivables, net1,1601,221
Inventories, net999976
Prepaid expenses and other current assets (Note 4)385383
Total current assets2,9222,977

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Bausch + Lomb's restricted cash?
Bausch + Lomb (BLCO) reported restricted cash of $11M in Q2 2026.
How has Bausch + Lomb's restricted cash changed year-over-year?
Bausch + Lomb's restricted cash increased by 83.3% year-over-year, from $6M to $11M.
What is the long-term trend for Bausch + Lomb's restricted cash?
Over 4 years (2021 to 2025), Bausch + Lomb's restricted cash has grown at a 47.0% compound annual growth rate (CAGR), from $3M to $14M.
What does restricted cash mean?
Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.

Ask your AI about Bausch + Lomb's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude